85.00PLN+3.53%Mkt Cap: 470.24M PLNP/E: —Last update: 2026-06-01
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap470.24M PLN
Enterprise Value—
Revenue (TTM)—
Gross Profit-2.04M PLN
Net Income (TTM)-15.16M PLN
Revenue/Share—
Last Price85.00 PLN
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLBCLTX00019
Valuation
P/E (Trailing)—
P/E (Forward)-43.21
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B14.97
EPS (TTM)-3.03
EPS (Forward)—
52W Range
70.0032% of range116.80
52W High116.80 PLN
52W Low70.00 PLN
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.69%
ROA-20.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.95M PLN
CapEx (TTM)1.97M PLN
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio—
Quick Ratio—
Book Value/Sh5.484 PLN
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)133.00 PLN
Target Range133.00 PLN – 133.00 PLN
# Analysts1
Ownership
Shares Out.5.53M
Float4.06M
Insiders19.77%
Institutions19.24%
Technical
SMA 5081.58 (+4.2%)
SMA 20088.28 (-3.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)5.38K
Avg Vol (10d)4.21K
Technical Indicators
RSI (14)47.7
MACD-0.4456
MACD Signal0.0258
MACD Hist.-0.4714
BB Upper88.65 PLN
BB Middle83.67 PLN
BB Lower78.68 PLN
BB Width11.91%
ATR (14)2.991 PLN
Vol Ratio (20d)0.94x